相关实验视频

Updated: Jun 5, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

线粒体状况对食道状细胞癌患者的生存影响

Kotaro Sugawara^1,2,3, Shingo Sakashita⁴, Takashi Fukuda²

¹Department of Pathology, Saitama Cancer Center, Saitama, Japan.

Annals of surgical oncology

|December 7, 2024

概括

在新辅助化疗 (NAC) 前的低线粒体得分 (Mito-score) 与食道状细胞癌 (ESCC) 患者的生存率较差有关. 这一发现对晚期疾病尤为重要.

科学领域:

在瘤学瘤学.
细胞生物学细胞生物学
癌症研究癌症研究

背景情况:

接受新辅助化疗 (NAC) 和手术的食道状细胞癌 (ESCC) 患者的线粒体状况尚不清楚.
调查ESCC的预后标志物对于改善患者的治疗结果至关重要.

研究的目的:

为了评估线粒体状况的影响,通过Mito-score评估,在接受NAC的ESCC患者的整体存活期 (OS).
探索Mito-score,瘤特征,免疫微环境和对NAC的反应之间的关联.

主要方法:

分析了260个NAC前ESCC患者样本,使用基于免疫组织化学的Mito-score系统.
基于队列中位数和评估的免疫标志物 (CD4,CD8,Foxp3,HLA类-1,Ki-67,PD-L1) 的二体化线粒评分.
利用多变量Cox危险模型来识别OS的独立预测因素.

主要成果:

在更先进的瘤 (cT3-4) 和对NAC反应良好的人群中观察到更高的线粒子评分.
线粒高的瘤显示CD8细胞和Ki-67表达的增加.
较低的Mito-score与较差的OS (3年OS:57.6%与68.2%,p=0.03) 有显著的关联,特别是在晚期 (III-IV).
多变量分析证实了低的Mito-score作为不良OS的独立预测指标 (HR 1.59,p=0.009).

结论:

在NAC前的低Mito-score是ESCC患者的显著负面预后因素,特别是那些患有晚期疾病的人.
线粒体状况可能会影响瘤的攻击性和NAC响应性,影响患者的存活率.
线粒评分可以作为一种有价值的生物标志物,用于管理ESCC患者.

关键词:

食管状细胞癌的癌症线粒体中的线粒体.新辅助化学疗法新辅助化学疗法瘤微环境是一个微环境.

更多相关视频

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Author Spotlight: Transmitochondrial Cybrid Generation Using Cancer Cell Lines

Published on: March 17, 2023

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...